Study of SB-BCLmR-HSPC (BCL11A Enhancer approach) for treatment of transfusion-dependent beta-thalassemia major
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2017
At a glance
- Drugs SB-BCLmR-HSPC (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions; Therapeutic Use
- 06 Jan 2017 According to a Sangamo Therapeutics media release, this trial was originally conducted by Sangamo BioSciences but later on this company's name changed to Sangamo Therapeutics.
- 13 May 2015 According to a Sangamo BioSciences media release, the decision to change to a BCL11A Enhancer approach will delay the initiation of this trial and it is now expected to begin in 2016.
- 13 May 2015 Status changed from not yet recruiting to planning, according a Sangamo BioSciences announcing that a new IND application will be submitted for a BCL11A Enhancer approach.